{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:52:23Z","timestamp":1783021943009,"version":"3.54.6"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"am","delay-in-days":319,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016599","name":"Purdue Institute for Drug Discovery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1CA069202"],"award-info":[{"award-number":["RO1CA069202"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejmech.2024.117129","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T16:48:20Z","timestamp":1733503700000},"page":"117129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Structure-activity relationship studies and design of a PTPN22 inhibitor with enhanced isozyme selectivity and cellular efficacy"],"prefix":"10.1016","volume":"283","author":[{"given":"Brenson A.","family":"Jassim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad J.","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5527-7910","authenticated-orcid":false,"given":"Zhong-Yin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117129_bib1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/0968-0004(94)90134-1","article-title":"The coordinated action of protein tyrosine phosphatases and kinases in cell signaling","volume":"19","author":"Sun","year":"1994","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2024.117129_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nrm2039","article-title":"Protein tyrosine phosphatases: from genes, to function, to disease","volume":"7","author":"Tonks","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.117129_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ceb.2009.01.028","article-title":"Tyrosine phosphorylation: thirty years and counting","volume":"21","author":"Hunter","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.117129_bib4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/febs.12077","article-title":"Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction","volume":"280","author":"Tonks","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2024.117129_bib5","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/0008-5472.CAN-17-1510","article-title":"Therapeutic targeting of oncogenic tyrosine phosphatases","volume":"77","author":"Frankson","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117129_bib6","series-title":"Protein Tyrosine Phosphatases in Cancer","author":"Neel","year":"2016"},{"key":"10.1016\/j.ejmech.2024.117129_bib7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/aps.2014.80","article-title":"Protein tyrosine phosphatases as potential therapeutic targets","volume":"35","author":"He","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2024.117129_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc2980","article-title":"Inside the human cancer tyrosine phosphatome","volume":"11","author":"Julien","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.117129_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14728222.10.1.157","article-title":"Targeting the PTPome in human disease","volume":"10","author":"Tautz","year":"2006","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2024.117129_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117129_bib11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the 'undruggable' cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.117129_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/acs.accounts.6b00537","article-title":"Drugging the undruggable: therapeutic potential of targeting protein tyrosine phosphatases","volume":"50","author":"Zhang","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2024.117129_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1021\/cb300597g","article-title":"Challenges and opportunities in the development of protein phosphatase-directed therapeutics","volume":"8","author":"De Munter","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.117129_bib14","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2174\/092986709788612693","article-title":"Drug discovery and protein tyrosine phosphatases","volume":"16","author":"Blaskovich","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib15","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/med.21871","article-title":"Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug discovery","volume":"42","author":"Elhassan","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.117129_bib16","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1038\/s41467-023-38952-1","article-title":"Systematic literature review reveals suboptimal use of chemical probes in cell-based biomedical research","volume":"14","author":"Sterling","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.117129_bib17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2174\/1568026033452302","article-title":"An overview of the protein tyrosine phosphatase superfamily","volume":"3","author":"Wang","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev-immunol-032713-120249","article-title":"Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease","volume":"32","author":"Bottini","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2024.117129_bib19","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood.V93.6.2013.406k25_2013_2024","article-title":"Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp","volume":"93","author":"Cohen","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117129_bib20","doi-asserted-by":"crossref","first-page":"11002","DOI":"10.1074\/jbc.M600498200","article-title":"Identification of substrates of human protein-tyrosine phosphatase PTPN22","volume":"281","author":"Wu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib21","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1172\/JCI45790","article-title":"The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans","volume":"121","author":"Menard","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2024.117129_bib22","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.4049\/jimmunol.0713370","article-title":"Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling","volume":"182","author":"Arechiga","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2024.117129_bib23","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.4049\/jimmunol.179.7.4704","article-title":"Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes","volume":"179","author":"Rieck","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2024.117129_bib24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fimmu.2020.00376","article-title":"Phosphatase PTPN22 regulates dendritic cell homeostasis and cDC 2 dependent T cell responses","volume":"11","author":"Purvis","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2024.117129_bib25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/eji.201747092","article-title":"Protein tyrosine phosphatase PTPN22 regulates IL-1\u03b2 dependent Th17 responses by modulating dectin-1 signaling in mice","volume":"48","author":"Purvis","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejmech.2024.117129_bib26","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.4049\/jimmunol.1600604","article-title":"PTPN22 is a critical regulator of fc\u03b3 receptor-mediated neutrophil activation","volume":"197","author":"Vermeren","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2024.117129_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072384","article-title":"Protein tyrosine phosphatase non-receptor type 22 modulates NOD2-induced cytokine release and autophagy","volume":"8","author":"Spalinger","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.117129_bib28","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.4049\/jimmunol.1200150","article-title":"PTPN22 alters the development of regulatory T cells in the thymus","volume":"188","author":"Maine","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2024.117129_bib29","doi-asserted-by":"crossref","first-page":"ra87","DOI":"10.1126\/scisignal.2003365","article-title":"Lack of the phosphatase PTPN22 increases adhesion of murine regulatory T cells to improve their immunosuppressive function","volume":"5","author":"Brownlie","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2024.117129_bib30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nchembio.916","article-title":"LYP inhibits T-cell activation when dissociated from CSK","volume":"8","author":"Vang","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.117129_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ng1323","article-title":"A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes","volume":"36","author":"Bottini","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2024.117129_bib32","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.2337\/diabetes.53.11.3020","article-title":"Replication of an association between the lymphoid tyrosine phosphatase locus (LYP\/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus","volume":"53","author":"Smyth","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2024.117129_bib33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1086\/422827","article-title":"A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis","volume":"75","author":"Begovich","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2024.117129_bib34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1086\/468189","article-title":"PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis","volume":"77","author":"Carlton","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2024.117129_bib35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1086\/423790","article-title":"Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE","volume":"75","author":"Kyogoku","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2024.117129_bib36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.20751","article-title":"Association of the PTPN22\u2217R620W polymorphism with autoimmune myasthenia gravis","volume":"59","author":"Vandiedonck","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejmech.2024.117129_bib37","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.humimm.2009.04.027","article-title":"The autoimmunity-related polymorphism PTPN22 1858C\/T is associated with anti-titin antibody-positive myasthenia gravis","volume":"70","author":"Greve","year":"2009","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.ejmech.2024.117129_bib38","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/sj.gene.6364243","article-title":"A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo","volume":"6","author":"Canton","year":"2005","journal-title":"Gene Immun."},{"key":"10.1016\/j.ejmech.2024.117129_bib39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/17460441.2022.2084607","article-title":"PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy","volume":"17","author":"Jassim","year":"2022","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117129_bib40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2174\/13894501113146660236","article-title":"Lymphoid-specific tyrosine phosphatase (Lyp): a potential drug target for treatment of autoimmune diseases","volume":"15","author":"Du","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2024.117129_bib41","doi-asserted-by":"crossref","first-page":"19767","DOI":"10.1073\/pnas.0706233104","article-title":"Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases","volume":"104","author":"Yu","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.117129_bib42","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1021\/jm101004d","article-title":"Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids","volume":"54","author":"Vang","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib43","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1021\/jm400248c","article-title":"A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases","volume":"56","author":"He","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib44","doi-asserted-by":"crossref","first-page":"9309","DOI":"10.1021\/jm500692u","article-title":"Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening","volume":"57","author":"Hou","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib45","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1074\/jbc.RA118.007129","article-title":"Identification and structure-function analyses of an allosteric inhibitor of the tyrosine phosphatase PTPN22","volume":"294","author":"Li","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104124","article-title":"Design, synthesis and biological evaluation of imidazolidine-2,4-dione and 2-thioxothiazolidin-4-one derivatives as lymphoid-specific tyrosine phosphatase inhibitors","volume":"103","author":"Liang","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146950","article-title":"Systemic inhibition of PTPN22 augments anticancer immunity","volume":"131","author":"Ho","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2024.117129_bib48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jinorgbio.2009.12.012","article-title":"Gold(I) phosphine mediated selective inhibition of lymphoid tyrosine phosphatase","volume":"104","author":"Karver","year":"2010","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2024.117129_bib49","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1021\/jm101202j","article-title":"Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells","volume":"54","author":"Stanford","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/cmdc.201300404","article-title":"Covalent inhibition of the lymphoid tyrosine phosphatase","volume":"9","author":"Ahmed","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.117129_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115599","article-title":"Discovery of benzofuran-2-carboxylic acid derivatives as lymphoid tyrosine phosphatase (LYP) inhibitors for cancer immunotherapy","volume":"258","author":"Liang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib52","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.drudis.2011.11.007","article-title":"Bridging solubility between drug discovery and development","volume":"17","author":"Di","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2024.117129_bib53","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/jm101356p","article-title":"Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry","volume":"54","author":"Ishikawa","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib54","doi-asserted-by":"crossref","first-page":"14046","DOI":"10.1021\/acs.jmedchem.1c01215","article-title":"Bioisosteres of the phenyl ring: recent strategic applications in lead optimization and drug design","volume":"64","author":"Subbaiah","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib55","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1021\/tx200135s","article-title":"Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines","volume":"24","author":"Turesky","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2024.117129_bib56","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117129_bib57","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.jmedchem.2c01648","article-title":"Targeted protein degradation induced by HEMTACs based on HSP90","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T18:59:18Z","timestamp":1741287558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424010110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":57,"alternative-id":["S0223523424010110"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117129","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-activity relationship studies and design of a PTPN22 inhibitor with enhanced isozyme selectivity and cellular efficacy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117129"}}